Virtual Library

Start Your Search

Luis Eduardo Pino Villareal



Author of

  • +

    EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Treatment in the Real World - Support, Survivorship, Systems Research
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.16-13 - Characteristics and Clinical Outcomes in Patients with Non-Small Cell Lung Carcinoma in Fundacion Santa Fe De Bogota: 42 Months Experience (Now Available) (ID 2759)

      08:00 - 18:00  |  Author(s): Luis Eduardo Pino Villareal

      • Abstract
      • Slides

      Background

      The source of information available about lung cancer caracteristics and clinical outcomes in Colombia are poor.

      Method

      Observational, descriptive study of a cohort of patients with non small cell carcinoma (NSCL) treated at Fundacion Santa Fe de Bogota (FSFB). We followed patients from August 2015 to January 2019 (42 months) and analyzed clinical and epidemiological characteristics, progression free survival (PFS), overall survival (OSm) and treatment related complications.

      Result

      Forty-eight patients were included. 56.2% stage IV, 16.6% stage III, 8.3% stage II and 18.75% stage I. Stage IA (44%) received management with surgery, stage IB (56%) were treated with surgery and adjuvant therapy no patients progressed or died. In stage II all were IIA and received management with surgery and adjuvant therapy, 25% progressed and died OSm 26m and PFS 10m. In stage III group, IIIA (62.5%) treated with surgery and chemo-radiotherapy, 40% progressed PFS 12m, and OSm has not been reached. In stage IIIB (37.5%) received chemo-radiotherapy, 33% progressed PFS 8m and OSm has not been reached. In stage IV, the group without PDL-1 expression and negative for oncogenic addiction (22.5%) received treatment with chemotherapy OSm was 16.9m and PFS 7.5m. EGFR positives (41.9%) received target therapy, OSm was 25.8m and PFS 13.1m. The patients with ALK rearrangement (9.6%) were treated with target therapy OSm was 16m and PFS 12.6m. For PDL-1 >50% (12.9%) all received monoagent immunotherapy OSm was 11m and PFS 10m. For PDL-1 1-49% (12.9%) PFS was 28m and OSm has not been reached, they were treated with inmunotherapy plus chemotherapy. In relation with grade 3 toxicity with adjuvant chemotherapy was 10% diarrhea, 10% kidney failure, 10% hematotoxicity, 10% decompensation of heart failure previously diagnosed. In metastatic disease 7% with chemotherapy had kidney failure, 7% emesis, 7% diarrhea and 7%% hyporexia. Patients with target therapy 17% had diarrhea and 11% hepatotoxicity, 5% hematotoxicity, 5% dermatological complications. 9% with bevacizumab presented hemoptysis and 6% of patients with immunotherapy had autoimmune colitis. Hypothyroidism was the most frequent complication with the immunotherapy 37%.

      Conclusion

      We had important proportion of stages I-II (27%). Recurrent disease was more frequent in stage III as had been described. Factors like cigarette, nutritional status and ECOG were no statistically significant for the survival. In metastatic setting the highest OS and PFS was for the group with PDL-1 expression between 1-49%, treated with chemotherapy plus immunotherapy.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.